Jump Trading LLC purchased a new stake in Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,435 shares of the medical equipment provider’s stock, valued at approximately $259,000.
A number of other large investors have also recently made changes to their positions in the business. Brown Advisory Inc. boosted its holdings in Boston Scientific by 3.0% in the 3rd quarter. Brown Advisory Inc. now owns 60,451 shares of the medical equipment provider’s stock valued at $1,763,000 after purchasing an additional 1,771 shares during the period. Moors & Cabot Inc. boosted its holdings in Boston Scientific by 3.7% in the 3rd quarter. Moors & Cabot Inc. now owns 49,975 shares of the medical equipment provider’s stock valued at $1,468,000 after purchasing an additional 1,800 shares during the period. IFM Investors Pty Ltd boosted its holdings in Boston Scientific by 5.5% in the 3rd quarter. IFM Investors Pty Ltd now owns 39,091 shares of the medical equipment provider’s stock valued at $1,140,000 after purchasing an additional 2,038 shares during the period. Bessemer Group Inc. lifted its holdings in shares of Boston Scientific by 28.9% during the 4th quarter. Bessemer Group Inc. now owns 10,288 shares of the medical equipment provider’s stock worth $255,000 after acquiring an additional 2,305 shares during the last quarter. Finally, LS Investment Advisors LLC lifted its holdings in shares of Boston Scientific by 6.3% during the 4th quarter. LS Investment Advisors LLC now owns 43,176 shares of the medical equipment provider’s stock worth $1,070,000 after acquiring an additional 2,555 shares during the last quarter. 91.04% of the stock is owned by hedge funds and other institutional investors.
BSX has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed a “top pick” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Monday, March 5th. Canaccord Genuity dropped their price objective on shares of Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, November 29th. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. Zacks Investment Research downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, ValuEngine downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $31.16.
Boston Scientific Co. (NYSE BSX) opened at $27.62 on Tuesday. The stock has a market cap of $38,401.27, a PE ratio of 394.57, a price-to-earnings-growth ratio of 2.02 and a beta of 0.82. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.68 and a quick ratio of 0.49. Boston Scientific Co. has a 52-week low of $24.02 and a 52-week high of $29.93.
Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.34. The firm had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.27%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS. equities research analysts expect that Boston Scientific Co. will post 1.37 EPS for the current fiscal year.
In other news, EVP Joseph Michael Fitzgerald sold 85,227 shares of Boston Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $26.48, for a total transaction of $2,256,810.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael P. Phalen sold 15,835 shares of Boston Scientific stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $25.25, for a total transaction of $399,833.75. The disclosure for this sale can be found here. Insiders have sold a total of 217,079 shares of company stock worth $5,804,645 in the last ninety days. Insiders own 0.74% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Jump Trading LLC Purchases New Holdings in Boston Scientific Co. (BSX)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/03/20/jump-trading-llc-purchases-new-holdings-in-boston-scientific-co-bsx.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.